NCM
INDV icon

Nearwater Capital Markets’s Indivior Pharmaceuticals INDV Stock Holding History

Nearwater Capital Markets’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-60,000
Closed -$2.15M – 109
2025
Q4 		$2.15M Hold
60,000
– – 0.04% 101
2025
Q3 		$1.45M Buy
+60,000
New +$1.26M 0.02% 144

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nearwater Capital Markets's INDV Position: Q1 2026 in Review

Nearwater Capital Markets sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 60,000 shares — an estimated $2.15M sold.

Nearwater Capital Markets first reported a position in INDV in Q3 2025 and held it in 2 quarters. The position peaked at $2.15M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Nearwater Capital Markets reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nearwater Capital Markets sold 60,000 Indivior Pharmaceuticals shares in Q1 2026, an estimated $2.15M.
  • Nearwater Capital Markets first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Nearwater Capital Markets's Indivior Pharmaceuticals position peaked at $2.15M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Nearwater Capital Markets's 13F filing for Q1 2026, filed 15 May 2026.